5-2016

Diffusion Modeling and Device Development for Peritoneal Membrane Oxygenation

Liana Hatoum
University of Nebraska - Lincoln, liana.hatoum@hotmail.com

Follow this and additional works at: http://digitalcommons.unl.edu/mechengdiss

Part of the Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, Biomedical Devices and Instrumentation Commons, Cardiovascular Diseases Commons, and the Pulmonology Commons

http://digitalcommons.unl.edu/mechengdiss/96

This Article is brought to you for free and open access by the Mechanical & Materials Engineering, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Mechanical (and Materials) Engineering -- Dissertations, Theses, and Student Research by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
DIFFUSION MODELING AND DEVICE DEVELOPMENT FOR PERITONEAL MEMBRANE OXYGENATION

by

Liana Hatoum

A THESIS

Presented to the Faculty of
The Graduate College at the University of Nebraska
In Partial Fulfillment of Requirements
For the Degree of Master of Science

Major: Mechanical Engineering and Applied Mechanics

Under the Supervision of Professor Benjamin S. Terry

Lincoln, Nebraska

May, 2016
Acute respiratory distress syndrome (ARDS) is a pulmonary disease that causes hypoxemia and respiratory failure. The mortality rate for ARDS ranges between 27% and 45%. Current treatments including mechanical ventilation and extracorporeal membrane oxygenation (ECMO) are often associated with high risk complications including barotrauma, infection, thrombosis, and hemorrhage. Alternative pulmonary support techniques are needed to improve the survival rate of patients suffering from ARDS. Previous studies introducing pure O$_2$ gas, perfluorocarbons and red blood cells into the intraperitoneal (IP) cavity have reported no effect or only a mild increase in oxygenation. Here we report peritoneal membrane oxygenation (PMO) using phospholipid-coated oxygen microbubbles (OMBs). OMBs are oxygen carriers that have unique physical and chemical properties. We hypothesize that IP infusion of OMBs can provide supplementary oxygenation for rats with ARDS and hypoxemia, thus allowing time for essential recovery of the lungs.

We designed a bolus delivery device that automatically and periodically infuses OMBs to the rat’s IP cavity. In addition, the device flushes the cavity with saline, scavenges the perfusate, maintains safe intra-abdominal pressure, and regulates perfusate temperatures to body temperature.

In order to understand the mechanism by which intraperitoneal OMB infusion improves systemic oxygenation, we examined, both in theory and in vivo, the kinetics of
oxygen transport from OMBs to blood capillaries of healthy rats. A 1D mathematical model was developed using Fick’s laws to predict the oxygen diffusion rate across the peritoneum. *In vivo* measurements of the gas content of OMBs after 20 minutes of dwell time in the IP cavity of rats were further used to determine the oxygen diffusion rate, which was found to be within the predicted range. Also, we are able to demonstrate *in vivo* that OMBs not only can provide O₂ to the body, but also can absorb CO₂ and possibly other gases, such as N₂, from the body. PMO represents an alternative extrapulmonary technique of oxygenation and ventilation that is a potential treatment for acute respiratory failure in the future.
Acknowledgements

A special thanks to my adviser and committee chairman Dr. Benjamin Terry for giving me the opportunity to become a research assistant in his lab and for his guidance, leadership, and timely advice over the course of the study. I learned and gained valuable experience in his lab.

I wish to thank the rest of my thesis committee, Dr. Keely Buesing and Dr. Angela Pannier, who were more than generous with their expertise and precious time. Thank you for agreeing to serve on my thesis committee and for your assistance and insightful comments.

I am very grateful for Dr. Jeffrey Shield and Dr. Mehrdad Negahban for giving me the opportunity of becoming a teaching assistant in the first semester of my master’s degree. I also wish to thank Kathie Hiatt and Mary Ramsier for their administrative support throughout these years.

I would like to express my gratefulness to PhD student, Nathan Legband, for his great help and for assisting me throughout the study and all of the lab members for their positive feedback.

In addition, I wish to thank Dr. Mark Borden and PhD student, Alec Thomas, from the University of Colorado-Boulder for their collaboration and for fabricating the oxygen microbubbles used in this study. I would like to acknowledge Dr. Douglas Hostetler and Craig Kreikemeier-Bower who helped us in performing the animal
surgeries. In addition, thanks to UNL’s Institutional Animal Care staff in housing and caring for the animals used in this study.

Research reported in this thesis was supported by the University of Nebraska Bioengineering Seed Grant No. 507, Nebraska Research Initiative Grant, and DHHS-NHLBI of the NIH under award number 1 R21 HL129144-01. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH.

Last but not least, my deepest thanks to my husband Hadi for his continuous motivation and support. He was of great help with editing this thesis and other published papers. This work is dedicated to my wonderful parents, my sisters, and my late grandmother.
Table of Contents

Chapter 1: Introduction ................................................................. 1

1.1 Scope and Organization of Thesis ........................................... 1

1.2 Acute Respiratory Distress Syndrome ...................................... 2

1.2.1 Pathophysiology of ARDS .................................................. 2

1.2.2 Available Treatment for ARDS ............................................ 5

1.2.3 Classification and Prognosis of ARDS ................................. 7

1.3 Peritoneal Membrane Oxygenation ......................................... 7

1.4 Research Objectives ............................................................... 13

Chapter 2: Aspiration of OMBs from the Intraperitoneal Space .......... 14

2.1 Introduction ........................................................................... 14

2.2 Materials and Methods .......................................................... 14

2.3 Statistical Analysis .................................................................. 16

2.4 Results and Analysis .............................................................. 17

Chapter 3: OMB Infusion Device ................................................... 20

3.1 Introduction ........................................................................... 20

3.2 Materials and Methods .......................................................... 21

3.2.1 OMB storage .................................................................. 22

3.2.2 Infusion ........................................................................... 23
Appendix B: Temperature Circuit Design ................................................................. 65
Appendix C: SolidWorks Drawings ............................................................................. 66
Appendix D: Modeling Program .................................................................................. 68
List of Figures

Figure 1.1 Lung alveoli (a) normal and (b) ARDS .................................................. 3

Figure 1.2 Chest X-ray (a) normal patient showing clear lung fields and (b) patient with ARDS showing bilateral diffuse infiltrates [11] [12] .................................................. 4

Figure 1.3 Available treatment for ARDS patients. (a) Mechanical ventilation and (b) ECMO ........................................................................................................... 6

Figure 1.4 Peritoneal dialysis [24] .............................................................................. 8

Figure 1.5 (a) OMB vial and (b) microstructure of OMBs [34] ........................................ 10

Figure 2.1 Items tested for aspirating OMBs (a) Side opening teat tube and (b) peritoneal lavage catheter .................................................................................................. 16

Figure 2.2 Aspiration volumes (mean ± SD) of OMBs using different items. Significant difference is indicated by ‘***’ (p<0.001) .............................................................................. 18

Figure 3.1 Schematic of the bolus delivery system for conscious rats ............................. 21

Figure 3.2 Humidifier for OMBs ..................................................................................... 22

Figure 3.3 Peristaltic pump used for infusion .................................................................. 24

Figure 3.4 Pressure measurement and display .................................................................. 25

Figure 3.5 Fluid warmer .................................................................................................. 27

Figure 3.6 PCB for temperature measurement .................................................................. 27

Figure 3.7 Rat tether [42] ............................................................................................... 29

Figure 3.8 Electronics box .............................................................................................. 30

Figure 3.9 LabVIEW control user interface ..................................................................... 31

Figure 3.10 Oxygen saturation taken by pulse oximetry [43] ........................................... 33
Figure 4.1 Simplified model of oxygen diffusion from OMBs to the layers of the peritoneum ................................................................. 37

Figure 4.2 Simplified model of oxygen diffusion from OMBs to the layers of parenchymal tissue ................................................................................. 38

Figure 4.3 Mathematical model of 1D diffusion of oxygen from OMBs to peritoneal blood over time ................................................................................. 40

Figure 5.1 Experimental setup for headspace gas analysis of OMBs ......................... 44

Figure 5.2 Pictures taken during experiment (a) OMB extraction (b) implanted catheters (c) crushed OMBs (d) headspace gas analysis ................................................................. 44

Figure 5.3 Pulse oximeter measurements (LS-mean) include (a) heart rate (beats per minute) and (b) oxy-hemoglobin saturation (%) before and after OMB bolus injection to the rat’s IP cavity (n = 4) ................................................................................................................................. 46

Figure 5.4 (a) Gas vol% composition (average ± SD) of OMBs and (b) gas content of OMBs after OMB infusion to the cavity (n = 4) ................................................................................................................................. 47

Figure B.1 Temperature circuit board design using Altium ........................................ 65

Figure C.1 Lower face dimensions of electronics box ................................................. 66

Figure C.2 Top face dimensions of electronics box .................................................... 67

Figure C.3 Side face dimensions of electronic box ...................................................... 67
List of Tables

Table 1.1 Berlin criteria for defining ARDS [20]............................................................ 7

Table 1.2 Oxygen carrying capacity at body temperature and atmospheric pressure ...... 11

Table 2.1 Size of the needles and catheters tested for aspiration of OMBs...................... 17

Table 2.2 Frequency of omental occlusion occurred using each item (n=5)...................... 18

Table 5.1 Diffused volume (average ± SD) of gases in mL between OMBs and surrounding tissue during dwell in IP space (n = 4) ................................................................. 49

Table 5.2 Modeled versus experimental diffusion rate (J), diffusion depth (L) and oxygen supply............................................................................................................................. 50

Table A.1 Recorded volumes of aspirated OMBs from IP space in rats (n = 5)......... 64
Chapter 1: Introduction

Acute respiratory failure is a life threatening condition in which the respiratory system fails in one or both of its gas exchange functions, which include oxygenation and CO₂ elimination [1] [2]. Treatment of patients with severe respiratory failure requiring mechanical support is done in an intensive care unit. Acute respiratory distress syndrome (ARDS) is the most severe form of acute lung injury. It is a rapidly progressive disease that leads to low oxygen levels in blood known as hypoxemia. According to a study in 2005, about 190,000 people in the U.S. develop ARDS annually [3]. Many people who develop ARDS do not survive due to its high mortality, which can be as high as 45% [4]. The risk of death increases with age and severity of illness. Of the people who do survive ARDS, some recover to near-normal function while others experience lasting damage to their lungs. In this study we explore a possible way of oxygenation hoping that this technique may be useful to decrease the morbidity and mortality of patients suffering from ARDS in the near future.

1.1 Scope and Organization of Thesis

Chapter one focuses on the background knowledge on ARDS required to understand the motivation behind this study. Chapter two describes the experimental design and results for finding a reliable way to remove oxygen microbubbles (OMBs) from the intraperitoneal (IP) cavity after injection. Chapter three describes the design and development of an automatic oxygen microbubble (OMB) delivery device, which can be
used for testing the effectiveness of peritoneal membrane oxygenation (PMO) as a treatment for ARDS rats. Chapter four includes the modeling work done to predict the kinetics of oxygen diffusion from OMBs to venous blood in peritoneum tissue. Chapter five describes \textit{in vivo} experiments for gas analysis of OMBs after injection to the IP cavity of rats. Chapter five is a discussion of the findings and conclusions.

1.2 Acute Respiratory Distress Syndrome

1.2.1 Pathophysiology of ARDS

The human lungs are a pair of spongy, air-filled respiratory organs located on either side of the thoracic cavity in the chest. At the microscopic level are small air sacs called alveoli (Figure 1.1 a). Between the walls of the alveoli is a thin layer of cells called the interstitium, which contains cells, fibers, and blood vessels that help support the alveoli. The thickness of the alveolar-capillary barrier is 0.65 µm [5]. The total surface area of the alveoli is approximately 75 m² in humans, which is similar to the surface area of a tennis court [6]. Oxygen diffuses from the air in the alveoli to the blood in the small capillaries surrounding the alveoli, while CO₂, a waste product of metabolism, diffuses from the blood to the alveoli, where it can be exhaled.

At the microstructure level, ARDS affects the alveoli in the lungs. Direct or indirect lung injury initiates an inflammatory-immune response that activates neutrophils, macrophages, and platelets to the injured sites [7]. Circulating neutrophils adhere to the endothelium of pulmonary capillaries and release chemical mediators resulting in damage to the alveolo-capillary membrane allowing fluid release from the capillary filling the
When protein rich edema fluid accumulates in the alveolar space, this obstructs the lungs from oxygenating the blood thus leading to hypoxemia (Figure 1.1b). In addition, neutrophils pass through the leaky capillaries and produce an inflammatory response in the lung epithelium, resulting in further damage to the lungs and respiratory decompensation [9]. The release of inflammatory mediators from damaged lung tissue triggers a systemic inflammatory immune response causing multi-organ failure, which is the main cause of death in ARDS patients [10].

Figure 1.1 Lung alveoli (a) normal and (b) ARDS
Radiographically, a chest X-ray shows bilateral diffuse infiltrates occupying most of the lung fields indicating ARDS (Figure 1.2b). A normal chest X-ray shows clear lung fields (Figure 1.2a).

Figure 1.2 Chest X-ray (a) normal patient showing clear lung fields and (b) patient with ARDS showing bilateral diffuse infiltrates [11] [12]

There are several causes of ARDS. Infectious etiologies such as sepsis, bacteremia and severe pneumonia are the most prominent. Systemic inflammatory conditions such as severe pancreatitis can also lead to ARDS. Inhalation of toxic chemicals or smoke can cause ARDS by direct injury to the alveoli and capillaries. In addition, traumatic injuries to the head or chest could contribute to the etiology of ARDS.
1.2.2 Available Treatment for ARDS

The first goal in treating ARDS is to improve the levels of oxygen in the blood to prevent organ failure. For mild disease, oxygen may be delivered through a mask that fits tightly over the nose and mouth to provide supplemental oxygenation. Most people with moderate or severe ARDS will need to be intubated and placed on a mechanical ventilator (MV) to either support or completely control the breathing of the patient (Figure 1.3a) [13]. MV pushes air into the lungs and forces some of the fluid out of the air sacs. It is currently the best treatment option available. However, MV does have side effects. Some patients experience alveolar hyperdistention and cyclic closing and reopening of the alveoli during positive pressure ventilation that leads to volutrauma (increased lung volume) and barotrauma (increased lung pressure). These traumatic changes in lung volume and pressure can lead to ventilator associated lung injury (VALI). VALI can then trigger a pulmonary and systemic inflammatory reaction that may lead multiple organ dysfunction and multiple system organ failure [10]. Although the mortality rate of respiratory illnesses decreased over recent years due to the advances in MV, it still remains high [14].

To support patients with severe ARDS who have failed MV or other conventional ventilator rescue techniques, researchers looked into the idea of extrapulmonary ventilation to bypass the damaged lungs and supply oxygen directly to the blood while allowing the lung injury to heal. Extracorporeal membrane oxygenation (ECMO) is an extracorporeal technique of providing respiratory support to patients whose lungs are unable to provide an adequate amount of gas exchange to sustain life [15]. This method
pumps blood out from the body into a diffusion membrane, artificially adding oxygen into the red blood cells (RBCs) and removing CO₂, and then pumps blood back to the patient (Figure 1.3b). ECMO was first introduced in the 1970’s [16]. Historically, ECMO use has centered on neonatal care [17]. A recent increase in adult ECMO use can be attributed to H1N1-induced ARDS across the globe. It is commonly used as a last resort treatment in patients suffering from very severe ARDS. The survival rate of ECMO is 47.7% [18]. ECMO is an invasive technique that has a high cost and complexity, which restrict its use in ambulatory situations. In addition, it is associated with high risk complications such as infection, thrombosis and hemorrhaging [19]. ECMO can support gas exchange in patients failing conventional mechanical ventilation, but proper patient selection and ultimate poor outcomes makes its use controversial. Therefore, alternative pulmonary support techniques are needed to improve the survival of patients with ARDS.

Figure 1.3 Available treatment for ARDS patients. (a) Mechanical ventilation and (b) ECMO
1.2.3 Classification and Prognosis of ARDS

In 2011 a panel of experts established the Berlin criteria to classify ARDS (Table 1.1). ARDS was best classified as mild, moderate and severe based on the ratio of partial pressure of arterial oxygen and fraction of inspired oxygen (PaO$_2$/FiO$_2$) [20]. This classification was also based on prognostic measures. As shown in the table below, the mortality rate and duration of mechanical ventilation is proportional to the severity of ARDS and PaO$_2$/FiO$_2$ ratio. Patients with severe disease having the highest oxygen need have a high mortality up to 45% and spend on average 9 days on the ventilator, while patients with mild disease have a lower mortality of 27% and spend an average of 5 days on the ventilator.

<table>
<thead>
<tr>
<th>ARDS</th>
<th>PaO$_2$/FiO$_2$</th>
<th>Mortality (95% CI)</th>
<th>Duration on Mechanical Ventilation (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>$\leq 300$</td>
<td>27% (24-30)</td>
<td>5</td>
</tr>
<tr>
<td>Moderate</td>
<td>$\leq 200$</td>
<td>32% (29-34)</td>
<td>7</td>
</tr>
<tr>
<td>Severe</td>
<td>$\leq 100$</td>
<td>45% (42-48)</td>
<td>9</td>
</tr>
</tbody>
</table>

1.3 Peritoneal Membrane Oxygenation

Alternative extrapulmonary respiration methods have been explored, such as peritoneal membrane oxygenation (PMO). This idea was first proposed in 1934 to mechanically ventilate the peritoneal cavity with oxygen [21]. This idea translates from
the concept of peritoneal dialysis. Peritoneal dialysis is a well-known technique that has been widely accepted for the treatment of end stage renal failure since 1923 [22]. This technique exchanges solute and fluid across the peritoneum and is simple and less expensive than hemodialysis (Figure 1.4) [23]. The most common complications from peritoneal dialysis include infection around the catheter site or infection of the lining of the abdominal wall also known as peritonitis.

![Peritoneal Dialysis Diagram](image)

Figure 1.4 Peritoneal dialysis [24]

The peritoneum is a thin, continuous, translucent membrane, which covers the visceral organs and the abdominal wall. It is composed of a mesothelial single cell layer, interstitial tissue and blood capillaries. The average surface area of the peritoneum membrane (PM) is 1.3 m² in adults [25]. PMO follows the same concept as dialysis, but uses the peritoneum for gas exchange. This method shows promise as it is a simple
procedure with easy access of the peritoneal cavity for catheterization, and relative safety with low risk complications compared to an extracorporeal circuit [26] [27].

One study observed the effects of transperitoneal ventilation with pure $O_2$ gas on death time in asphyxiated rabbits [28]. All animals died successively after asphyxia. In addition, there was no significant increase in $PaO_2$. This study failed because the surface area was minimized owing to the high surface free energy (~73 mJ/m$^2$) of the gas/water interface. Another study aimed to determine whether systemic oxygenation could be increased in pigs, with induced hypoxia, by perfusing the abdominal cavity with oxygenated perfluorocarbons (PFCs) [29]. The most clinically relevant results occurred at an FiO$_2$ of 14%, resulting in a baseline mean $PaO_2$ of 39.4 ± 5.0 mm Hg with oxygenated saline solution perfusion, and a mean $PaO_2$ of 55.3 ± 7.6 mm Hg with oxygenated PFC perfusion. Infusion of RBCs into the intraperitoneal (IP) cavity of dogs resulted only a mild increase in oxygen partial pressures [30]. These prior attempts have not been able to show clinically relevant results. This may be due to the low biocompatibility and low oxygen transfer efficiencies of the oxygen carrier utilized, which might explain their failure to oxygenate the body. The most successful application of peritoneal oxygenation used liposomal synthetic hemoglobin, which produced a mean increase in rat cardiac arrest time following a right pneumothorax from 9 to 33 min [31].

Our proposed solution is to use oxygen microbubbles (OMBs), an innovative oxygen carrier with unique physical and chemical properties. The original clinical utilities of gas-filled particles are as ultrasound contrast agents filled with an inert insoluble gas and drug delivery vehicles [32]. Such suspensions are not well suited for
gas delivery because they are typically designed to have low gas fractions and prolonged circulation. However, OMBs (70% vol) are designed to be smaller than 15 μm in diameter suspended in saline (30% vol). They contain pure O₂ gas core encapsulated by a phospholipid monolayer composed of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and polyethylene glycol (PEG) brush combined in a 9:1 molar ratio (Figure 1.5). PEG forms coils (~10 nm in height) that provide steric repulsion to prevent microbubble coalescence. The phospholipid monolayer membrane is 3 nm thick, which reduces surface tension and provides rigidity. The bubble’s shell comprises only ~1% of the total microbubble volume. OMBs mimic the structure and composition of natural lung alveoli. The bubble shell is highly permeable to O₂ and other gases, allowing continuous diffusive exchange with surrounding dissolved gases [33].

Figure 1.5 (a) OMB vial and (b) microstructure of OMBs [34]
A 70% volume suspension of OMBs at atmospheric pressure and 37 °C contains an estimated 0.88 mg-O_2/mL [34]. Table 1.2 compares the oxygen carrying capacity of RBCs, PFCs, liposomal hemoglobin (Hb), and pure oxygen gas. OMBs can carry oxygen 0.88 mg-O_2/mL, which is higher than other aqueous carriers used at same temperature and pressure. Although pure O_2 gas has 1.26 mg-O_2/mL, the oxygen carrying capacity is not the only criterion for efficient oxygen transport. Oxygen diffusion also depends on the surface area by Fick’s law relation. The overall rate of diffusion of gas is equal to the product of the flux and area. Pure oxygen gas in the peritoneal cavity has a high surface free energy (~73 mJ/m^2) of the gas/water interface. Thus, the surface area for diffusion is drastically minimized [34].

Table 1.2 Oxygen carrying capacity at body temperature and atmospheric pressure

<table>
<thead>
<tr>
<th>O_2 carrier</th>
<th>OMBs</th>
<th>RBCs</th>
<th>Liposomal Hb</th>
<th>PFC</th>
<th>O_2 gas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capacity (mg-O_2/mL)</td>
<td>0.88</td>
<td>0.31</td>
<td>0.62</td>
<td>0.57</td>
<td>1.26</td>
</tr>
</tbody>
</table>

A recent study by Kheir et al. [35] characterized the release kinetics of O_2 gas from OMBs to blood. When OMBs were mixed with human deoxygenated blood *ex vivo*, O_2 diffusion was complete within only 4 sec. They also investigated intravenous injection of OMBs in rabbit hypoxic ventilation and tracheal clamp asphyxiation. OMBs supplied the animals’ full oxygen consumption for 15 min, and decreased the incidence of cardiac arrest and organ injury from asphyxia. The intravenous treatment with OMBs appears to be a promising method for short-term rescue. However, prolonged continuous infusion of
OMBs into the bloodstream has risks of embolism, thrombosis, and toxicities of lipid and saline that remains in blood circulation. Therefore, a different approach is needed for long term therapy of ARDS avoiding complications associated with injection of OMBs into the bloodstream.

Previous work has shown that OMBs delivered intraperitoneally maintain hemoglobin oxygen saturations at normal levels and provide 100% survival for rats with a right-sided pneumothorax for at least 2 hours. In comparison, untreated rats and rats treated with peritoneal oxygenated saline died within 30 min [34]. Another study showed that PMO therapy can double the survival time of rabbits after complete tracheal occlusion from 6.6 ± 0.6 min (average ± SD) for the saline controls to 12.2 ± 3.0 min for the bolus OMB treated rabbits [36]. These results show that OMBs have potential to be an alternative mechanism of oxygen delivery when injected intraperitoneally.

Previous work characterized the properties of OMBs ex vivo [37] [33], but there is a need to conduct research to study the rate of oxygen delivery in vivo. Also further studies are needed to test the potential of OMBs in absorbing CO₂ in vivo. Our team recently demonstrated that PMO can significantly increase survival in rats suffering a right pneumothorax and rabbits suffering complete tracheal occlusion. In order to proceed into a more clinically relevant disease model, the goal of the proposed study is to develop and test PMO therapy in a clinically relevant rat model of mild to severe ARDS in rats. We hypothesize that intraperitoneal infusion of OMBs can be used as a supplementary method of oxygen delivery and CO₂ removal for rats with ARDS thus allows time for essential recovery of the lungs.
1.4 Research Objectives

The overall goal of this research is to considerably increase the survivability of patients with ARDS by providing alternative extrapulmonary oxygenation using OMBs. In pursuit of this goal, the specific aims of this research is to first finalize the development and validation of an OMB delivery system that will automatically infuse and remove OMBs from the rat’s IP cavity. This device can be used for a long term study for testing PMO as a potential treatment for ARDS in rats.

We aim to understand the mechanism by which intraperitoneal OMB infusion improves systemic oxygenation, by examining the OMB gas exchange properties with the PM by both theoretical modeling and in vivo tests. A one dimensional mathematical model developed using Fick’s laws can predict the oxygen transport rate from OMBs to peritoneum blood. A model would help us understand in theory the kinetics of oxygen transport and how that would relate to the normal oxygen consumption need in rats. In addition, it can predict whether continuous infusion or periodic bolus infusion of OMBs is more efficient in oxygen delivery. One way for experimental validation of the model is by measuring O$_2$ delivery and CO$_2$ removal by OMBs after infusion to the IP cavity of rats. These measurements can be used to calculate the oxygen diffusion rate in vivo and compared to our modeled oxygen kinetics. Finally, we aim to determine the optimal perfusion dosage and dwell time of OMBs in the IP cavity of rats.
Chapter 2: Aspiration of OMBs from the Intraperitoneal Space

2.1 Introduction

Injection of OMBs into the IP cavity of rats can be applied by a needle or a catheter implanted in the lower abdomen. The purpose of this experiment is to find a reliable aspiration technique of OMBs after an IP injection. Aspiration is needed in experiments involving studying the gas content of OMBs after dwelling in the IP space. In addition, IP infusion of OMBs for several days to treat ARDS will lead to accumulation of saline and lipids in the IP cavity. If intra-abdominal pressure exceeds safe limits this could interfere with the hemodynamics of the abdomen and limit the blood supply to abdominal organs. In order to prevent inducing abdominal compartment syndrome, OMBs need to be removed from the IP space. Previous attempts by our group to aspirate the injected OMBs after dwelling in rat’s IP cavity were unsuccessful using small needles. In this experiment, different needle diameters were tested, in addition to a side opening teat tube (SOTT), and a peritoneal lavage catheter (PLC) (Figure 2.1a,b).

2.2 Materials and Methods

Male Wistar rats \( (n = 5, \ m = 539 \text{ g}) \) were housed and acclimated for four days, and cared for according to the University of Nebraska-Lincoln Institutional and Animal Care and Use Committee (IACUC) guidelines. All rats were sedated using ketamine-
xylazine (18-2 mg/kg) and placed in the supine position on a warming pad (T/pump Classic, Gaymar) set at 38 °C to maintain body temperature. Paw pinches were made to verify full sedation. The rat was then placed in a supine position on the surgery table.

Previous studies showed that an IP volume injection of 60 mL was considered to be safe for ~ 500 g rats [38] [39]. OMBs were stored in a cooled environment at 5 °C prior to the experiment to preserve their composition and structure. A 60 mL syringe was used to extract OMBs from the vial, and the syringe was left at room temperature for 5 minutes. A 60 mL single bolus of OMBs was injected into the IP cavity within 1 minute. After injection, OMBs were allowed to dwell for 2 minutes so that OMBs were naturally distributed inside the cavity. After dwell, OMBs were manually aspirated by pulling out the plunger of the syringe. The volume of OMBs aspirated was recorded, and the aspirated OMBs were transferred into a waste beaker. The same volume of fresh OMBs was injected in the IP cavity using the next larger needle and allowed to dwell for 2 minutes. This preserves a total of 60 mL OMBs in the IP cavity. Three different methods were tested, which include needles of increasing size (18G, 16G, 14G, 11G, and 10G), an SOTT, and a PLC (JP7, Mila International, Erlanger, KY) catheter were tested. Table 2.1 shows the inner diameter (ID) and length of the needles, SOTT, and PLC used. For the 11G, 10G, and SOTT, a scalpel was used to make a small incision in the lower right quadrant of the abdominal cavity to accommodate for the larger diameters. All items were placed in the same incision to minimize injury to the rat. For placing the catheter, a small incision into the skin was made to expose the fascia of the abdominal wall. A PLC
outflow catheter (PLC) was surgically implanted in the IP cavity and sutured to the skin.

Finally, the rat was sacrificed using CO2 inhalation.

2.3 Statistical Analysis

Multiple t-tests assuming equal variances was performed on the volumes of aspirated OMBs to test for any differences between all groups. All tests used the same level of significance ($\alpha = 0.05$).

Figure 2.1 Items tested for aspirating OMBs (a) Side opening teat tube and (b) peritoneal lavage catheter
Table 2.1 Size of the needles and catheters tested for aspiration of OMBs

<table>
<thead>
<tr>
<th>Size</th>
<th>Needles</th>
<th>Cannula</th>
<th>Catheter</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>18G</td>
<td>16G</td>
<td>14G</td>
</tr>
<tr>
<td>ID (mm)</td>
<td>0.8</td>
<td>1.2</td>
<td>1.6</td>
</tr>
<tr>
<td>Length (cm)</td>
<td>2</td>
<td>3.8</td>
<td>2.5</td>
</tr>
</tbody>
</table>

2.4 Results and Analysis

The aspirated volumes of OMBs are shown in Appendix A. The means ± SD were plotted on a bar graph in Figure 2.2. The PLC had the highest average of aspired volume of 30 ± 6.3 mL. There is significant statistical difference between the means of PLC and each of SOTT, 10G, 14G, and 18G needles (‘***’ p<0.001).

Volumes of approximately 0 mL OMBs aspirated were due to omental occlusion (OO). Occlusion occurs when fatty abdominal tissue (omentum) occludes the tip of the needle while applying a suction force using the syringe. Table 2.2 summarizes the frequency of OO occurrence for each item. Occurrence of omental occlusion (per 5 rats) was between 2 to 4 using needles (between 18G and 10G) compared to none using the lavage catheter. In other words, during aspiration needles had a high failure rate of 50–80%, while the PLC had 0% failure.
Table 2.2 Frequency of omental occlusion occurred using each item (n=5)

<table>
<thead>
<tr>
<th>Item</th>
<th>18G</th>
<th>16G</th>
<th>14G</th>
<th>11G</th>
<th>10G</th>
<th>SOTT</th>
<th>PLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frequency of OO</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

Figure 2.2 Aspiration volumes (mean ± SD) of OMBs using different items. Significant difference is indicated by ‘***’ (p<0.001)

The needles had a wide range of aspiration volumes of spent OMBs ranging from 0 to 43 mL. The variation was mainly due to the high probability of omental plug during aspiration. PLC successfully aspirated an average of half of the injected OMBs, with a relatively low SD over the 5 trials. PLC has proven to be the most reliable and efficient
method to extract the OMBs. Its advantages over needles and SOTT are its flexibility, wider diameter, its numerous pores and increased length that allows a large surface area in the IP cavity and subsequently allows better aspiration of OMBs. Thus, PLC can be used for long term studies were it can be surgically implanted in the IP cavity unlike needles or SOTT. In addition, the PLC can be used in experiments that require extraction of OMBs from the IP space for gas content measurements.
Chapter 3: OMB Infusion Device

3.1 Introduction

The mortality rate of patients with ARDS remains high even with the advancements in mechanical ventilation and ECMO. Alternative extrapulmonary ventilation techniques such as peritoneal membrane oxygenation are still being explored as a potential therapy for ARDS. With the development of a promising oxygen carrier, a device is needed to deliver OMBs intraperitoneally. The system will be used for studying PMO with conscious and ambulatory rats of mild to severe ARDS. To evaluate improvements of oxygen levels in blood and survivability, the length of the study will be at least 3 days after inducing ARDS to rats and administering OMB treatment. Manual infusion and removal of the perfusate to the cavity is a time consuming and exhaustive procedure. In addition, continuous or periodic infusion of OMBs for several days results in accumulation of lipids and saline (30% vol) in the IP space thus could limit the blood supply to abdominal organs if IP pressure exceeds safe limits. Therefore, an automatic system for infusion and scavenging of OMBs is needed for this study.

The design of the delivery device was established in a manner similar to peritoneal dialysis catheter placement. A preliminary design was developed for continuous infusion of OMBs, which consisted of two catheters implanted in the cavity, one for inflow, and PLC for outflow. However, in vivo testing of the continuous infusion system first prototype revealed advanced tissue obstruction and growth in the PLC after four days. This was a major problem as it prevented further removal of fluid from the
cavity. In addition, OMBs need to dwell in the cavity for gas exchange to occur (Chapters 4 and 5). Therefore, the design was revised to implement a periodic bolus system that is simpler and effective. This chapter focuses on describing the current bolus delivery system. The device will automatically infuse and scavenge OMBs, maintain safe intra-abdominal pressure, and regulate perfusate temperatures to body temperature.

3.2 Materials and Methods

A schematic of the delivery system (Figure 3.1) includes OMB storage, periodic infusion of OMBs, intra-abdominal pressure (IA) pressure measurement and control, temperature measurement and control, tubing restraint, data acquisition and LabVIEW control.

Figure 3.1 Schematic of the bolus delivery system for conscious rats
3.2.1 OMB storage

OMBs require a cool, rotating, and pure humid O$_2$ environment to avoid breakdown of the lipid monolayer in the bubbles. The OMB vial is stored in a container at a temperature between 2-8 °C and placed on a rotating table. The OMB vial is connected to an inlet line for supplying pure O$_2$ gas, an O$_2$ outlet line to avoid overpressurizing the vial, and an OMB supply line (Figure 3.2). To avoid evaporation of the saline in OMBs, pure O$_2$ gas is supplied to a closed vial containing water, which supplies humidified O$_2$ gas to the OMBs vial.

Figure 3.2 Humidifier for OMBs
3.2.2 Infusion

The fluid infusion system necessary to supply OMBs without exposing the infusing fluid to the pump and surrounding atmosphere. The system delivers OMBs by a peristaltic pump (FH100M, Thermo Fisher Scientific, Waltham, MA) shown in Figure 3.3. OMBs pass from the storage vial through tubing, connectors, valves, and swivel before reaching the cavity. This closed loop system avoids air contamination of OMBs to preserve their oxygen content. The system requires only a single peritoneal catheter that is used as both an inflow and outflow line. The PLC is tunneled subcutaneously to the back of the rat where they are fixed to a custom pedestal at least 3 days prior to the beginning of the study. The perfusion circuit includes connecting tubing to the infusion/scavenge ports of the PLC to the pump. The pump has a flow rate range of 0.013-760 mL/min and a maximum output of 200 rpm. This pump has an extended rotor head for multiple tubing lines, which allows the ability to infuse multiple subjects or multiple fluids. The adjustable cartridges allow most tubing diameters to be used for infusing. The pump has a DB-25 input/output with 0-10 V, which allows for it to be controlled using a LabVIEW program.
3.2.3 Pressure Measurement and Control

In order to prevent over pressurizing the cavity that could limit blood flow to the region and can lead to abdominal compartment syndrome, IA pressure is measured and maintained between 0 – 6 mmHg [40] [41]. For measuring the IA pressure of rats non-invasively, a pressure transducer (S7d, Gaeltec Devices Ltd, Isle of Skye, UK) is inserted into a catheter for continuously reading pressure throughout the length of the study. The sensor (6 French) is inserted into the inflow/outflow line at a negligible height over the catheter port to avoid inaccuracy in the IA pressure reading.

The S7d is powered by a low voltage mains adaptor 9V DC with sensitivity of 5μV/V/mmHg. For completely accurate pressure measurements, the transducer is compared to a calibrated pressure sensor. The transducer is connected to an amplifier.
(S7d pressure transducer amplifier, Gaeltec Devices Ltd), which has an LCD display and is connected to a 4 channel box (Figure 3.4). Also, it has an analog voltage output port that can be connected to a data acquisition system.

![Image of pressure measurement equipment and display](image-url)

**Figure 3.4 Pressure measurement and display**

Pressure is regulated through the use of a fluidic control solenoid valve controlled by LabVIEW. In case IA pressure exceeds 6 mmHg, the outflow solenoid valve opens and a scavenge phase is initiated so that OMBs are extracted from the IP cavity until the IA pressure goes back to the safe range.
3.2.4 Temperature Measurement and Control

OMBs are stored at low temperatures to preserve their structure and stability for approximately 7-10 days. Before infusing OMBs in bolus volumes to the rat’s IP cavity, they need to be warmed close to body temperature to avoid inducing hypothermia. The fluid warmer (i-Warm, Midmark, Kettering, OH) is a dry-heat device designed for warming I.V. fluids safely through the heating plate (Figure 3.5). Measurements of the temperature of the OMBs both in their storage and after passing through the fluid warmer are needed to verify they are within the required ranges. To measure the temperatures, a K-type thermocouples are used. One sensor is placed in a T connector at the fluid warmer exit line. Another sensor is placed in the OMB storage to verify the temperature is between 2-8 ºC. The thermocouple output is amplified with an AD595-AQ amp (Burr-Brown, Digikey, Thief River Falls, MN). The output of the amplifier is 10 ºC/mV. The project circuit board (PCB) is designed on Altium to connect the electronics (Appendix B). The circuit includes two K-type thermocouples, two amplifiers, +5 V power supply, ground, and two voltage outputs. The PCB is then fabricated by the UNL Engineering Electronics Shop (Figure 3.6).
Figure 3.5 Fluid warmer

Figure 3.6 PCB for temperature measurement
3.2.5 Tubing restraint

In order to prevent tubing from restraining the rat or being damaged by the rat, a spring restraint is originally designed with a spring retractor and a counter balance weight. Preliminary trials of the first prototype revealed that this tubing restraint did not work properly. One rat managed to reach the tubing and pull on his catheter. Therefore, a new design for a rat tether is under development.

The tubing will be tethered to the infusion pump via a custom swing arm that keeps the tubing suspended above the rat and prevents entanglement (Figure 3.7). Once in the cage, the animal will have free access to food and water.

Tethered systems require an in-dwelling catheter, a harness, and swivel. Tethered infusion is a commonly employed technique in laboratory animals, especially rats. This is the only option for long-term continuous access in rats [42]. The rat harness serve to protect the catheter port and with minimal stress, a means of restraining the animal.

In addition, a counterbalance serves to reduce the weight load that the animal experiences from the tether and swivel. An important component between the rat and the pump is the swivel, which serves as a rotary fluid seal. Without the swivel, the animal would be significantly encumbered in its movement, and the fluid line would occlude partially or totally.
3.2.6 Data Acquisition

To connect the peristaltic pump to the DAQ (USB-6003, National Instruments, Austin, TX), a DB-25 break out board (Winford Engineering, Auburn, MI) is required. Figure 3.8 shows the electronics box that includes 4 solid state relays, a breakout board, DAQ, and temperature PCB. The acrylic box design using SolidWorks is shown in Appendix C.
3.2.7 LabVIEW Control

The delivery device includes a LabVIEW interface shown in Figure 3.9 to control several key parameters such as rat’s mass, pump speed, and type of infusate, which is either saline or OMBs. In addition, the program provides manual override that allows the user to control the pump and the four solenoid valves or stop the system completely. The control program automatically calculates the bolus volume (BV) based on the rat’s mass (M) as: \( BV \text{ (mL)} = \frac{M \text{ (g)}}{10} \)
For preliminary trials to test the continuous system, male Wistar rats (n = 2, m ~ 500 g) were successfully administered aerosolized (Lipopolysaccharide) LPS endotoxin to induce ARDS. One rat was continuously infused OMBs at 0.5 mL/min for 12 hours and the other for 24 hours. Another trial was conducted on a rat for 4 days for testing the automatic infusion and scavenging system. Benchtop tests were conducted on the final design of the automatic bolus system.

3.3 Results and Analysis

In ARDS rats, $S_pO_2$ decreased steadily following administration of endotoxin in untreated controls while $S_pO_2$ increased after 24 hours for ARDS rats treated with OMBs.
(Figure 3.10). The device lacked automatic scavenging with a waste flow line. Instead, excess OMBs were removed by manually drawing them out from the cavity with a syringe connected to the PLC every 2 hours.

One preliminary trial on a rat was conducted with the automatic continuous infusion and scavenging system and it revealed that there was advanced tissue obstruction and growth in the PLC after four days. This may be caused by the constant suction applied to the outflow line leading to suction of tissue inside the pores of the lavage catheter.

Benchtop testing of the final design of the bolus delivery system has been successfully completed. The tubing restraint was not working properly. The new design of the rat tether is still under development. The bolus delivery system will be tested on rats to ensure that infusion and scavenging can be maintained for two weeks. Once testing is successful, we will proceed with validation trials with saline, inert gas microbubbles, and OMBs.
Figure 3.10 Oxygen saturation taken by pulse oximetry [43]
Chapter 4: Diffusion Modeling

4.1 Introduction

A previous theoretical and experimental study was undertaken by Borden et al. to determine the fate of a microbubble suddenly suspended in a multi-gas environment, such as the bloodstream [33]. They developed a numerical model based on the classic Epstein and Plesset theory that predicts the rate of microbubble dissolution in a single gas medium. Experimental verification of the model was performed with individual sulfur hexafluoride (SF$_6$) microbubbles coated with a soluble surfactant. Microbubbles placed in a perfusion chamber containing N$_2$ and O$_2$ in an aqueous medium initially grew due to the influx of nitrogen and oxygen and then dissolved under surface tension.

In contrast, our study involves infusion of oxygen filled microbubbles into the intraperitoneal cavity of rats with ARDS. This is a new method being explored that requires more studies in theory and in vivo. A lack of literature on modeling oxygen delivery from OMBs to peritoneum tissue prompted a need for this study. In addition, there is not enough data that support one method of infusion in delivering oxygen (bolus vs. continuous circulation). A model for diffusion would predict how fast oxygen diffuses across the multiple layers of tissue in the surrounding abdomen. Depending on how fast diffusion reaches steady state, this would determine the maximum dwell duration of OMBs. A simple 1D mathematical model was developed using Fick’s laws to determine the oxygen transport rate and how it compares to the normal oxygen consumption need.
4.2 Materials and Methods

For OMBs injected into the IP cavity of rats, the pathway of gas exchange across the PM is assumed to be homogeneous and has one spatial dimension for simplification. OMBs are assumed to have a constant $O_2$ concentration when injected in the IP cavity and no oxygen is consumed by surrounding tissue. The gas components are assumed to behave ideally and no convection occurs.

Oxygen molecules move down their concentration gradient diffusing out of OMBs to reach RBCs in the PM blood capillaries (Figure 4.1). To reach the capillaries in the peritoneum, oxygen must first dissolve in the saline of the OMBs and then diffuse through the mesothelium, cells and interstitial tissue. To reach the capillaries in the parenchymal tissue beneath the PM, oxygen must first dissolve in the saline of the OMBs and then diffuse through the PM layers and muscle tissue (Figure 4.2). The rate of diffusion depends on the surface area of the PM and the flux density. Increasing the area or the concentration gradient leads to faster diffusion. The diffusion rate using Fick’s first law is written as

$$J = -AD \left( \frac{dC}{dx} \right)_{x=L} = -AD \frac{C_0 - Cs}{L} \quad (1)$$

where the diffusion zone is equal to the thickness ($L$) of the tissue between the OMBs and blood capillary wall, $C_0$ and $Cs$ are the dissolved $O_2$ concentrations in blood capillaries and in the peritoneal cavity, respectively, $D$ is the diffusivity, and $A$ is the surface area of the PM, which can be calculated using the rat’s mass ($M$) [44]

$$A \text{(in cm}^2\text{)} = 1.61M \text{(in g)} + 40.5 \quad (2)$$
The dissolved gas concentration at equilibrium depends on both partial pressure \(P\) and solubility \(\alpha\) according to Henry’s law

\[ C = \alpha P \]  

(3)

The parameters of solubility and diffusivity for \(\text{O}_2\) in plasma and tissue are 0.003 (mL/dL)/mmHg and \(1.7 \times 10^{-5}\) cm\(^2\)/s, respectively [45]. The PM has a reported thickness of approximately 90 \(\mu\)m in rats [46]. However, because rats have relatively few blood vessels in the peritoneum, most oxygen transport could end in parenchymal tissue blood vessels, which are below the PM at a thickness between 0.5 – 1 mm [47]. Both cases are examined in the calculation of the diffusion rate. If diffusion occurs over the PM by itself, \(\text{O}_2\) will be absorbed by blood capillaries at peritoneum thickness of 90 \(\mu\)m (case 1). In contrast, if diffusion reaches the visceral organ capillaries, then the average tissue thickness is 0.75 mm (case 2). We used Fick’s second law [48] that predicts how diffusion causes the concentration \(C_x\) to change with time. The solution to Fick’s second law [48] is

\[ \frac{C_x - C_0}{C_s - C_0} = 1 - \text{erf} \left( \frac{x}{\sqrt{2Dt}} \right) \]  

(4)

where \(x\) is the thickness of tissue and \(t\) is time.

MATLAB was used to solve and plot \(C_x\) (Appendix D). In addition, the oxygen supply from OMBs was compared to the oxygen metabolism in resting rats, which is \(~12\) mL/min/kg [49].
Figure 4.1 Simplified model of oxygen diffusion from OMBs to the layers of the peritoneum.
4.3 Results and Analysis

A simplified model for diffusion of oxygen from OMBs to the peritoneum blood was constructed. The mass of rats used in the mathematical model was 538 g, equal to the average mass of rats used in the in vivo experiments. Using equation 2, the peritoneal surface area was calculated to be 907 cm². The oxygen partial pressure ($P_{O2}$) in the peritoneal blood capillaries is normally 40 mmHg [50]. The average rat IP pressure measured after a single bolus injection of OMBs was ~2 mmHg above atmospheric pressure, so $P_{O2}$ in OMBs was 762 mmHg. Thus, the pressure gradient of OMBs-to-blood was 722 mmHg.
The oxygen content inside OMBs is 70 mL/dL, while O$_2$ bound to hemoglobin in RBCs has a concentration of 15 mL/dL within venous blood. However, the diffusion rate is driven by the dissolved oxygen concentration gradient. Using equation 3, the concentration of dissolved O$_2$ in venous blood is $C_0$, which is equal to 0.12 mL/dL, while the concentration of dissolved O$_2$ in OMB saline is $C_s$, which is equal to 2.29 mL/dL. The OMBs-to-blood dissolved O$_2$ concentration gradient is their difference of 2.17 mL/dL.

An algorithm was developed using MATLAB to solve and plot the oxygen diffusion kinetics. If the diffusion thickness is 90 µm, then the oxygen diffusion rate would be 0.038 mL/s, and this supplies 34.4% of the total oxygen consumption needed in rats. However, if the thickness is 0.75 mm, then the diffusion rate would be 0.0045 mL/s supplying only 4.2% of the total oxygen consumption of rats. Tissue at depth of 90 µm (Figure 4.3a) will reach O$_2$ concentration of 1.94 mL/dL within 1 minute. Steady state is reached after 35 seconds. Tissue at depth of 0.75 mm (Figure 4.3b), will reach O$_2$ concentration of 1.77 mL/dL within 30 minutes. Steady state is reached after 41.7 minutes.

These results show that in theory oxygen delivered by OMBs in vivo occurs at a range between 0.0045 and 0.038 mL/s. Since oxygen delivery requires time (up to 42 min) to reach steady state, a bolus dosage administered periodically to IP cavity would be more efficient and cost effective than continuous infusion of OMBs. A 60 mL bolus would require a maximum dwell time of approximately 42 min to reach steady state in diffusion, but further in vivo tests are required to validate this dwell time.
Figure 4.3 Mathematical model of 1D diffusion of oxygen from OMBs to peritoneal blood over time
Chapter 5: *In vivo* Study

5.1 Introduction

In chapter 4, we have developed a simple model that predicts oxygen delivery from OMBs injected intraperitoneally. In theory the oxygen diffusion rate was found to be between 0.0045 and 0.038 mL/s. This range for diffusion rate is relatively wide due to several modeling limitations including 1D pathway and no oxygen consumption by tissue considerations. To validate our model and to obtain a more precise oxygen transport rate, an *in vivo* experiment was designed. A previous study by Kheir et al. [35] showed that OMBs when mixed with deoxygenated blood *ex vivo* deliver O$_2$ in 4 sec. The purpose of this experiment is to study not only oxygen delivery by OMBs, but also possible CO$_2$ absorption and other gas(s) from surrounding tissue *in vivo*. To validate gas diffusion properties of OMBs *in vivo*, the gas content of OMBs was measured by a gas analyzer before and after injection to the rat’s IP cavity. Fresh OMBs ideally contain pure oxygen gas if handled carefully avoiding air contamination. Measured gas concentrations were further converted to volumes and diffusion rate and depth were calculated. The experimental results for diffusion were then compared to the modeled theoretical values.

5.2 Materials and Methods

Male Wistar rats ($n = 4, 538 \pm 48$ g) were housed and acclimated for four days, and cared for according to the University of Nebraska-Lincoln IACUC guidelines. All rats were sedated using ketamine-xylazine (18-2 mg/kg) and placed in the supine position
on a warming pad (T/pump Classic, Gaymar, Orchard Park, NY) set at 38 °C to maintain body temperature (Figure 5.1a). Pulse oximetry (PhysioSuite, Kent Scientific Corp., Torrington, CT) measurements were taken throughout the whole experiment to measure the heart rate (HR) and oxy-hemoglobin saturation ($S_pO_2$). The pulse oximeter clip was placed on the rat’s hind leg and data was recorded every second until the experiment was terminated. After the rat was fully sedated and unresponsive to pain delivered by paw pinches, a small incision into the skin was made to expose the fascia of the abdominal wall. An inflow tube (3.2 mm, Tygon) and outflow catheter (JP7, Mila International Inc, Erlanger, KY) were surgically implanted in the IP cavity and sutured closed (Figure 5.2b). A valve was placed on the exterior end of the outflow catheter to vacuum the line with a syringe. A pressure sensor (S7d, Gaeltec Devices Ltd., Isle of Skye, UK) and the injection syringe were connected to the inflow line. IP pressure was monitored and maintained below 6 mmHg to avoid disruption of hemodynamics in the rat’s abdomen [51] [40]. The gas content of a 10 mL OMB sample collected directly from the OMB vial was analyzed before injection ($t = 0$). A single 60 mL OMB bolus, a safe volume for intraperitoneal injection of fluid in rats [38], was infused within 1 minute into the IP cavity using the inflow line. Immediately after, the IP pressure was recorded. Subsequently, 10 mL OMB samples were collected from the IP cavity every 5 minutes. Samples were manually crushed in the syringe by applying pressure to the plunger and then placed on a heating pad (70 °C) for 10 minutes (Figure 5.1b). This technique broke the lipid monolayer of the OMBs and released the gas content of the sample into the headspace (Figure 5.2c). The gas headspace was carefully transferred to another syringe
to be analyzed by an O₂ and CO₂ headspace gas analyzer (Gaspace 6600, Illinois Instruments, Inc., Johnsburg, IL). The syringe containing the gas sample was introduced into the gas analyzer by auto-injection (Figure 5.1c and Figure 5.2d). The entire process avoided air contamination to get the most reliable reading. Finally, after 20 minutes and 4 OMB samples were collected rats were euthanized by CO₂ inhalation.

One way valves were a source of inevitable air contamination added to each sample. The total volume of contamination, V_{air}, was found to be approximately 0.85 mL and composed of atmospheric air. A species balance was used to find the adjusted sample concentrations (x_{sample}) for O₂, CO₂ and N₂ neglecting water vapor and other trace gases. The overall volume balance was found with the following equations.

\[
x_{O_2, sample} = x_{O_2, measured} \left( \frac{V_{air}}{V_{sample}} + 1 \right) - 0.21 \left( \frac{V_{air}}{V_{sample}} \right)
\]

(5)

\[
x_{N_2, sample} = (1 - x_{O_2, measured} - x_{CO_2, measured}) \left( \frac{V_{air}}{V_{sample}} + 1 \right) - 0.79 \left( \frac{V_{air}}{V_{sample}} \right)
\]

(6)

\[
x_{CO_2, sample} = x_{CO_2, measured} \left( \frac{V_{air}}{V_{sample}} + 1 \right)
\]

(7)

5.3 Statistical Analysis

A linear mixed model with repeated measures with AR(1) covariance structure followed by a t-test were performed on the estimated slopes and intercepts of recorded S_pO₂ data before injection and after injection of OMBs. A p-value threshold of 0.05 was considered statistically significant.
Figure 5.1 Experimental setup for headspace gas analysis of OMBs

Figure 5.2 Pictures taken during experiment (a) OMB extraction (b) implanted catheters (c) crushed OMBs (d) headspace gas analysis
5.4 Results and Analysis

Intraperitoneal pressure was recorded after OMB bolus injection. The average measurement was 1.93 ± 0.5 mmHg \((n = 4)\). Before injection of OMBs at time 0 (Figure 5.3), the rats’ average \(S_pO_2\) was approximately 83.8 ± 0.8\%, while the average HR was 231.0 ± 10.3 bpm. After OMB bolus injection and 20 minutes dwell time, \(S_pO_2\) increased to 86.2 ± 2.2\%, while HR decreased to 226.2 ± 9.0 bpm. The fitted linear regression model for \(S_pO_2\) data showed that the slope of the line before injection was \(-0.0043\) indicating that there was no change in \(S_pO_2\) and had no statistically significant increase with time \((p > 0.05)\). After injection of OMBs, there was a slight increase of \(S_pO_2\) after dwell with a slope of +0.057, which was found to be statistically significant \((p < 0.05)\) using the same model and statistical test.

After crushing the OMBs, the gas volume was recorded for each sample (Figure 5.4a). Fresh OMBs had 67\% gas volume fraction. This fraction decreased to 34.6 ± 8.2\% after 20 minutes of dwell time. The measured gas contents were adjusted for contamination using equations 5, 6 and 7. Figure 5.4b shows the adjusted gas content detected in OMBs before and after dwelling in the IP cavity. Fresh OMBs had an average of 93.8 ± 3.9\%, 0\% and 6.2 ± 3.9\% for \(O_2\), \(CO_2\) and \(N_2\), respectively. After 20 minutes of dwell time, OMBs had an average of 76.3 ± 7.7\%, 5.5 ± 1.2\% and 17.2 ± 7.6\% for \(O_2\), \(CO_2\) and \(N_2\), respectively.
Figure 5.3 Pulse oximeter measurements (LS-mean) include (a) heart rate (beats per minute) and (b) oxy-hemoglobin saturation (%) before and after OMB bolus injection to the rat’s IP cavity (n = 4)
Figure 5.4 (a) Gas vol% composition (average ± SD) of OMBs and (b) gas content of OMBs after OMB infusion to the cavity (n = 4)
Gas percentages obtained by the gas analyzer were further analyzed to determine the volume of O$_2$ that diffused from OMBs to the rat’s body. The calculated diffusion volumes of O$_2$, CO$_2$ and N$_2$ across the PM over 20 min are shown in Table 5.1. Negative values represent diffusion in the opposite direction, from the rat’s body into the OMBs. OMBs in the IP cavity had a total of 16.5 mL O$_2$ diffused over 20 minutes. This was equivalent to a diffusion rate of 0.014 mL/s. OMBs still carried 57.6% of their initial O$_2$ volume after 20 min of dwell. Using the obtained diffusion rate, the diffusion depth was calculated to be 236 µm, and the oxygen supply was 13.1% of the total need. These values were within the range of our calculated theoretical diffusion model shown in Table 5.2.

These results indicate that after 20 minute dwell duration, OMBs (60 mL) still carry more than half of their initial oxygen content. In theory, a 45 min dwell would be enough time for oxygen to diffuse. These results confirm our bolus volume and dwell time predicted by our model in chapter 4. Therefore, for ~ 500 g rats a bolus volume of 60 mL OMBs will be allowed to dwell for ~ 45 minutes in the IP cavity of rats. Additional trials are needed to test this dwell duration on hypoxic rats.
Table 5.1 Diffused volume (average ± SD) of gases in mL between OMBs and surrounding tissue during dwell in IP space (n = 4)

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>V_{OMB}s in IP</th>
<th>V_{O2} diffused</th>
<th>V_{CO2} diffused</th>
<th>V_{N2} diffused</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>60</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>5</td>
<td>60</td>
<td>9.8 ± 4.4</td>
<td>-0.4 ± 0.1</td>
<td>-5.2 ± 2.2</td>
</tr>
<tr>
<td>5+</td>
<td>50</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>10</td>
<td>50</td>
<td>-1.4 ± 5.5</td>
<td>-0.2 ± 0.2</td>
<td>2.3 ± 2.9</td>
</tr>
<tr>
<td>10+</td>
<td>40</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>15</td>
<td>40</td>
<td>4.4 ± 1.8</td>
<td>-0.2 ± 0.2</td>
<td>0.3 ± 0.9</td>
</tr>
<tr>
<td>15+</td>
<td>30</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>20</td>
<td>30</td>
<td>3.6 ± 1.8</td>
<td>-0.3 ± 0.2</td>
<td>0.3 ± 0.4</td>
</tr>
</tbody>
</table>
Table 5.2 Modeled versus experimental diffusion rate (J), diffusion depth (L) and oxygen supply

<table>
<thead>
<tr>
<th></th>
<th>Model</th>
<th>Experiment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Case 1</td>
<td>Case 2</td>
</tr>
<tr>
<td>Depth (µm)</td>
<td>90</td>
<td>750</td>
</tr>
<tr>
<td>Rate (mL/s)</td>
<td>0.038</td>
<td>0.0045</td>
</tr>
<tr>
<td>% O₂ supply</td>
<td>34.4</td>
<td>4.2</td>
</tr>
</tbody>
</table>
Chapter 6: Discussion and Conclusions

Our first experiment determined a reliable and efficient method to extract the OMBs from the intraperitoneal space. A peritoneal lavage catheter (JP7, Mila International) can be used for long term studies involving OMB treatment of rats with mild to severe ARDS. This catheter can be surgically implanted in the IP space and used for both infusion and scavenging of OMBs due to its flexibility, wide diameter, numerous pores, and increased length. In addition, this catheter can be used in experiments that requires extraction of OMBs from the IP space to test for CO₂ absorption and O₂ delivery by OMBs.

Testing the effect of PMO as a potential therapy for ARDS requires at least 3 days of treatment. Thus, rats need to be conscious and able to move freely around their cage during this study. We have designed and developed an infusion system that automatically and intermittently infuses bolus dosage of OMBs to a rat’s IP cavity. The system will be used for studying PMO with conscious rats of mild to severe ARDS. We have completed a pilot study (n = 2) to verify the benefits of PMO therapy utilizing a continuous infusion device. There appears to be short-term improvement in reduction of hypoxia using pulse oximeter measurements of S_pO₂. However, the preliminary trial revealed advanced tissue obstruction and growth in the catheter after four days. This was a major problem as it prevented further removal of fluid from the cavity. Therefore, the design was revised to implement a periodic bolus system that is simpler and effective. This would allow OMBs to dwell in the cavity for gas exchange to occur between OMBs and peritoneum blood. Benchtop testing of the final design of the bolus delivery system has been successfully
completed. Since the tubing restraint was not working properly, a new design of a rat tether will be developed and tested shortly. In future trials, rats will be infused with either a bolus of sterile oxygenated saline, inert gas microbubbles (IMBs) as controls or OMBs for PMO therapy with four rats from each group. Upon completion of the device, we will evaluate the effect of PMO therapy on survival, lung health, and oxygen saturation.

The significance of this study was to give a better understanding of how oxygen microbubbles exchange gas with peritoneal tissue when infused to the IP cavity. A model for diffusion predicted how fast oxygen will diffuse across the multiple layers of tissue in the surrounding abdomen and how that relate to the normal oxygen consumption need. In theory oxygen delivered by OMBs in vivo occurs at a range between 0.0045 and 0.038 mL/s. This would supply between 4.2% and 34.4% of the total oxygen consumption needed in resting healthy rats.

There are several limitations to this mathematical model. The O₂ consumption by tissue in surrounding abdominal wall and internal organs was not accounted for. Oxygen consumption by tissue would decrease the amount of oxygen absorbed by blood capillaries. Also, it was assumed that OMBs maintain pure oxygen concentration, which was not the case in vivo because other gases diffuse into the bubbles as shown in the headspace gas measurements. The mathematical model was based on time and one dimensional space because of the complicated model schemes required for the true dynamics of diffusion in the 3D abdomen.

The diffusion profile obtained from the in vivo study was compared to the modeled diffusion profile. The calculated diffusion zone (236 µm) was larger than the
thickness of the PM (90 µm), but less than the parenchymal tissue thickness (750 µm). This indicates that oxygen diffused past the PM to reach underlying tissue in the abdominal wall and internal organs, however oxygen did not diffuse to the entire depth of parenchymal tissue in rats (0.5-1 mm thick). In addition, the oxygen supplied by the OMBs (0.014 mL/s) was lower than the normal oxygen consumption of rats as expected because the study was conducted on healthy rats. In addition to having catheter problems using the continuous infusion system, these results changed our initial device design from continuous circulation of OMBs to bolus periodic delivery. A 60 mL OMB bolus would require a dwell time of approximately 45 min to reach steady state in gas exchange, but further in vivo tests are required to validate this dwell duration on ARDS rats.

Pulse oximeter data indicated that bolus injection of OMBs did not cause any harm to the animal’s condition. General anesthesia causes low oxygen saturation and HR measured by peripheral pulse oximetry [52]. After 20 min, there was a slight increase in \( \text{S}_\text{pO}_2 \) by \( \sim 2.5\% \). This increase was statistically significant though it may not be clinically relevant. These results indicate that peritoneal membrane oxygenation was not harmful and may be potentially effective in delivering oxygen to hypoxic rats.

The greater decrease in oxygen content (Figure 5.4b) measured at 5 min compared to the 10 min sample could be due to air contamination. The outflow line was manually vacuumed directly after implantation into the IP cavity. Since this is not a perfect vacuum and it is unlikely that oxygen was reentering the OMBs, residual air within the line may explain why the sample taken at 10 min had more \% \( \text{O}_2 \) than the 5 min sample. Another contributing factor could be that the gas volumes of the samples
was different. Fresh OMBs are composed of 70% O$_2$, 30% saline, and <1% lipids. After OMBs dwell in the IP cavity, gas diffuses from OMBs to the body and vice versa thus changing the ratio of gas to saline volume. More oxygen diffused from OMBs than other gases being absorbed by the bubbles, so the gas percentage decreased gradually with time.

One of the gases detected in OMBs was CO$_2$, which cannot be due to air contamination because room air has only 0.003% CO$_2$ [53]. This gives evidence that OMBs can uptake CO$_2$ from the body. Healthy rats have a low blood concentration of CO$_2$, which explains the low amount of CO$_2$ detected in OMBs after dwelling in the IP cavity. Other traces of gases are unknown but assumed to be N$_2$ because the nitrogen partial pressure in venous blood is 573 mmHg [54]. Venous P$_{N2}$ is much greater than venous P$_{CO2}$, P$_{O2}$, and P$_{H2O}$ which are 46, 40, and 47 mmHg, respectively. Fresh OMBs have P$_{O2}$ of 760 mmHg and P$_{N2}$ of 0 mmHg ideally. Thus, there is a high blood-to-OMBs nitrogen pressure gradient that leads to a flux of N$_2$ from surrounding venous tissue to OMBs dwelling in the IP space. This may be of great potential benefit for removal of excess nitrogen gas in decompression sickness, a common condition that affects divers [55]. Further testing will be conducted to validate the other gas(s) absorbed by OMBs.

In conclusion, we developed a preliminary mathematical model that portrays the kinetics of oxygen transfer between OMBs and the body. *In vivo* results show that oxygen was delivered from OMBs by diffusive transport through the peritoneum into the adjacent blood and tissue of the abdominal wall and internal organs. CO$_2$ was also able to diffuse from the body into OMBs. Also, peritoneal oxygenation with OMBs did not
negatively alter the physical condition of the rats. Both mathematical modeling and animal experiments were applied on healthy rats with normal levels of oxygenation and respiratory rate. This serves as a reference for future studies involving hypoxia. We are able to demonstrate in vivo that OMBs not only can provide O$_2$ to the body, but also can absorb CO$_2$ and possibly other gases, such as N$_2$, from the body. This is very significant as it provides an alternative extrapulmonary technique of ventilation that can have significant implications in the future.

Our future goals involve improving our model using advanced numerical methods or finite elements analysis (FEA) that would be more accurate in simulating diffusion of multiple gases [56]. The transport of O$_2$, CO$_2$, and N$_2$ will also be modeled in hypoxic conditions. During hypoxemia, a lower oxygen concentration in blood increases the OMBs-to-blood oxygen concentration gradient thus increases the oxygen diffusion rate. In contrast, CO$_2$ accumulation in blood and tissue during hypoxia will drive CO$_2$ diffusion in the opposite direction thus OMBs will absorb a higher amount of CO$_2$.

Future work will include in vivo experiments on a hypoxic rat model of acute respiratory distress syndrome where we predict faster transport of oxygen and a more significant removal of carbon dioxide from the body due to the respiratory system being compromised. The oxygen delivery rate will be evaluated in supplying enough oxygen to accommodate the compromised lungs. In addition, arterial blood gases will be taken before and after infusion of OMBs to rat’s IP cavity and tested for clinically significant increase in PaO$_2$. 
We will further study the potential side effects of infusing OMBs to the intraperitoneal space by conducting autopsy and toxicology tests of abdominal organs. In addition, one way to determine the fate of OMBs \textit{in vivo} would be to radioactively label the lipids to test their absorption or breakdown. In addition, radioactive labeling O$_2$ gas would be another way to detect the pathway of oxygen delivered by OMBs.

The Berlin criteria used for classifying ARDS may also be used as a selection criteria for patients requiring peritoneal membrane oxygenation. PaO$_2$/FiO$_2$ is an important determinant of low levels of oxygen in blood. Further literature review and research need to be conducted to find a suitable selection criteria for ARDS patients requiring PMO.

Patients with mild-to-moderate ARDS can be potentially treated with PMO either in tandem with current ventilation practices such as mechanical ventilation or by itself. Infusion of OMBs intraperitoneally would provide supplemental oxygenation to surrounding tissue in the abdomen and blood. Pulmonary ventilation supported by MV and supplemental extrapulmonary ventilation provided by PMO would supply enough oxygen that will hopefully prevent these patients to reach end stage ARDS. This would decrease the chance of these patients requiring ECMO, which has a high mortality rate. We foresee the implementation of peritoneal membrane oxygenation as a treatment and first response aid for respiratory distress in intensive care units and combat field settings in the future.
References


[12] Case 3 answers - Mechanical Ventilation - Sub-internship in Critical Care Medicine - Medeck 620 - University of Washington School of Medicine, (n.d.).


## Appendix A: Aspirated OMB Volumes

Table A.1 Recorded volumes of aspirated OMBs from IP space in rats (n = 5)

<table>
<thead>
<tr>
<th>Rats</th>
<th>18G</th>
<th>16G</th>
<th>14G</th>
<th>11G</th>
<th>10G</th>
<th>SOTT</th>
<th>PLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>30</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>19</td>
<td>8</td>
<td>18</td>
<td>11</td>
<td>16</td>
<td>37</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>23</td>
<td>1</td>
<td>0</td>
<td>6</td>
<td>11</td>
<td>33</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>43</td>
<td>0</td>
<td>3</td>
<td>20</td>
</tr>
<tr>
<td>5</td>
<td>4</td>
<td>35</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>7</td>
<td>30</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>1.8 ± 2.1</td>
<td>15.4 ± 15.2</td>
<td>1.8 ± 3.5</td>
<td>12.4 ± 18.7</td>
<td>3.4 ± 4.5</td>
<td>7.6 ± 6.1</td>
<td>30 ± 6.3</td>
</tr>
</tbody>
</table>
Appendix B: Temperature Circuit Design

Figure B.1 Temperature circuit board design using Altium
Appendix C: SolidWorks Drawings

Figure C.1 Lower face dimensions of electronics box
Figure C.2 Top face dimensions of electronics box

Figure C.3 Side face dimensions of electronic box
Appendix D: Modeling Program

Matlab code for predicting the concentration change with time of peritoneum tissue after injection of OMBs.

```matlab
s = input('Please select case(1)/(2): ');  
if s == 1  
x=0:.1:90; % thickness of PM (um)  
y=0:.1:60; %time (seconds)  
else  
x=0:1:750; % thickness of parenchymal tissue(um)  
y=0:1:1800;  
end  

D = 1.7*10^3; %Diffusion coefficient of oxygen in tissue (um2/s)  
C0=0.12; % concentration of oxygen in plasma (ml/dl)  
Cs=2.286; % concentration of oxygen in peritoneal cavity filled with OMBs(ml/dl)  

figure(2); hold on  
n = length(x);  

for i = 150:150:n  
X = x(i);  
K = ((C0-Cs)* erf(X./(2*sqrt(D.*y)))+Cs); %Solution to Fick's second law where K is concentration (ml/dl)  
plot(y,K,'LineWidth',3);  
end  
xlabel('Time (seconds)','FontSize',24)  
ylabel('O2 Concentration (mL/dL)','FontSize',24)
```